Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...

New research suggests semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, could help people reduce their alcohol consumption.

A recent review and meta-analysis of semaglutide studies found that this drug can significantly reduce the risk of ...

Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, which in turn could put many ...

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage of Wegovy® and Ozempic® is resolved. The FDA's assessment confirms the U.S. supply of these ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

Desperation for ‘weight-loss’ drug that’s used to treat type-2 diabetes is real. Break-ins at pharmacies have also been ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed ...

A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...